Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
human rotavirus, live attenuated-Sanofi Pasteur, a Sanofi Company-diphtheria-tetanus-pertussis
- Development stage
- Approved
- Lead developer
- Parent
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Oral
01
Overview
human rotavirus, live attenuated-Sanofi Pasteur, a Sanofi Company-diphtheria-tetanus-pertussis refers to a clinical trial regimen involving the concomitant administration of a live-attenuated human rotavirus vaccine (Rotarix) and the SHAN6 hexavalent vaccine (DTwP-HepB-Hib-IPV). SHAN6 is a fully liquid, ready-to-use vaccine developed by Sanofi Healthcare India that combines diphtheria toxoid, tetanus toxoid, whole-cell pertussis (wP), hepatitis B surface antigen (HBsAg), Haemophilus influenzae type b (Hib) conjugate, and inactivated poliovirus (IPV) antigens. This combination is designed to provide comprehensive protection against seven major pediatric infectious diseases. The regimen was evaluated in a Phase 3 clinical trial (NCT04429295) in Thailand to assess its immunogenicity and safety when given alongside other routine pediatric vaccines, such as the 13-valent pneumococcal conjugate vaccine (Prevnar 13).
- Brand names
- SHAN6SHAN-6SHAN 6Rotarix
- Other names
- DTwP-HepB-Hib-IPV + Rotavirus vaccineSHAN6 + Rotarix
02
Targets
RVA (Rotavirus A)HBsAg (Hepatitis B surface antigen)TT (Tetanus toxoid)
Beyond the preview
Go deeper on human rotavirus, live attenuated-Sanofi Pasteur, a Sanofi Company-diphtheria-tetanus-pertussis.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on human rotavirus, live attenuated-Sanofi Pasteur, a Sanofi Company-diphtheria-tetanus-pertussis.